UNSPSC 51282103: Azidocillin

This classification denotes a penicillin antibiotic with the molecular formula C16H17N5O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R8XDP7L3SL, chemically known as 6-(2-azido-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-4-azabicyclo(3.2.0)heptane-2-carboxylic acid but generally known as azidocillin, which bears US NIH Compound Identifier 71886. Azidocillin most often comes in base, natrium, and sodium forms.

UNSPSC 51282103 Azidocillin is a Commodity code that nominally covers a specific antibiotic, but recent state and local solicitations tagged with this code show little alignment with that narrow scope. Instead, the opportunities reflect purchases of emergency medical supplies, naloxone, pharmaceuticals, and pharmacy benefit program services. The issuing bodies include county health departments, city fire departments, state health commissions, and multistate cooperative purchasing consortia. Work being solicited ranges from emergency responder consumables and harm-reduction supplies to generic pharmaceutical procurement and direct-to-manufacturer prescription fulfillment programs.

Geographic activity spans Florida, Texas, and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) serving multiple jurisdictions including Oregon. Representative recent opportunities include Seminole County, Florida's IFB 60459723LAS for naloxone and drug deactivation systems (1,900 units annually, due July 26, 2023), the City of Tampa's Bid 26P00145 for medical and first aid supplies to the Fire Department Rescue Division (estimated $700 million, with a sheltered-market designation for Small Local Business Enterprises and a 5 percent SLBE bid discount not to exceed $10,000, due March 13, 2026), MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products (RFP due March 26, 2026, with contract effective July 1, 2026), and the Texas Health and Human Services Commission's RFI HHS0017013 seeking vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program (due April 3, 2026). The mismatch between the code's nominal pharmaceutical identity and the actual scope of recent solicitations signals that this code may be mislabeled in state and local procurement systems or used as a catch-all for health-related consumables and pharmacy services.